Valuation: Novavax, Inc.

Market Cap 1.53B 1.34B 1.24B 1.14B 2.17B 146B 2.21B 14.79B 5.81B 72.08B 5.76B 5.64B 248B P/E 2026 *
-19.7x
P/E 2027 * -36.7x
Enterprise Value 1.75B 1.53B 1.41B 1.31B 2.48B 167B 2.52B 16.9B 6.64B 82.37B 6.58B 6.44B 283B EV / Sales 2026 *
4.28x
EV / Sales 2027 * 7.11x
Free-Float
93.03%
Yield 2026 *
-
Yield 2027 * -
1 day-0.74%
1 week-4.21%
Current month-0.96%
1 month+3.32%
3 months+14.90%
6 months+28.34%
Current year+38.84%
1 week 8.88
Extreme 8.885
9.69
1 month 8.26
Extreme 8.265
10.12
Current year 6.76
Extreme 6.76
11.97
1 year 6.2
Extreme 6.2
11.97
3 years 3.53
Extreme 3.5324
23.86
5 years 3.53
Extreme 3.5324
277.8
10 years 3.53
Extreme 3.5324
331.68
Manager TitleAgeSince
Chief Executive Officer 59 23/01/2023
Director of Finance/CFO 60 16/08/2021
Chief Tech/Sci/R&D Officer - 01/01/2022
Director TitleAgeSince
Director/Board Member 73 06/08/2010
Director/Board Member 66 01/11/2018
Director/Board Member 60 16/06/2020
Date Insider Type Main position Quantity % Market Cap.
06-20Fiscal year

Director

37,760 0.0230%
06-20Fiscal year

Director

37,760 0.0230%
06-20Fiscal year

Director

37,760 0.0230%
Change 5-day change 1-year change 3-year change Capi.($)
-0.74%-4.21%+36.40%-3.01% 1.53B
+0.58%+2.06%+3.90%+10.40% 50.73B
-2.22%-1.25%+391.53%+591.38% 39.73B
-0.54%+0.39%+27.67%-3.89% 34.69B
-1.36%+0.35%+19.34%+58.83% 33.21B
+1.21%-4.58%+3.00%+37.03% 26.76B
-1.81%-1.48% - - 16.8B
+0.51%-3.47%+66.38%+125.61% 15.37B
+0.23%-0.58%+13.80%+19.56% 13.78B
-0.62%-3.09%+11.43%-29.93% 12.85B
Average -0.48%-1.17%+63.72%+89.55% 24.54B
Weighted average by Cap. -0.48%-0.26%+82.44%+125.27%

Financials

2026 *2027 *
Net sales 410M 359M 331M 305M 580M 39.1B 589M 3.95B 1.55B 19.26B 1.54B 1.51B 66.22B 258M 226M 209M 193M 365M 24.65B 372M 2.49B 978M 12.14B 970M 949M 41.75B
Net income -79.31M -69.37M -63.98M -59.1M -112M -7.56B -114M -764M -300M -3.73B -298M -291M -12.81B -43.22M -37.81M -34.87M -32.21M -61.11M -4.12B -62.14M -417M -164M -2.03B -162M -159M -6.98B
Net Debt 219M 192M 177M 163M 310M 20.89B 315M 2.11B 829M 10.29B 822M 804M 35.37B 303M 265M 245M 226M 429M 28.92B 436M 2.92B 1.15B 14.25B 1.14B 1.11B 48.98B
Logo Novavax, Inc.
Novavax, Inc. is a biotechnology company. It is focused on addressing global health challenges through its vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M adjuvant. Matrix-M can be used to create vaccines for a variety of diseases to help tackle some of the pressing health challenges. Its proprietary Matrix-M adjuvant, when added to vaccines, has been shown to help induce a stronger and longer-lasting immune response. Its recombinant protein-based nanoparticle technology has been shown to be highly immunogenetic. Its technology platform is used in its authorized COVID-19 vaccine and the R21/Matrix-M adjuvant malaria vaccine. Its late-stage programs include a COVID-19-Influenzavaccine candidate, and an influenza vaccine candidate. R21/Matrix-M adjuvant malaria vaccine, a malaria vaccine developed by its partner. It provides Matrix-M adjuvant for use in various programs in preclinical and clinical stage, and preclinical investigations.
Employees
749
Date Price Change Volume
10/07/26 $9.330 -0.74% 5,096,243
09/07/26 $9.400 +0.53% 2,718,592
08/07/26 $9.350 -1.16% 3,793,610
07/07/26 $9.460 +1.18% 4,517,345
06/07/26 $9.350 -4.00% 2,958,090
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
9.330USD
Average target price
14.11USD
Spread / Average Target
+51.27%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NVAX Stock